Establishments: Trends, Employee Statistics, State by State numbers
Valued added statistics: industry GDP contribution
Competitive LandscapeIndustry Concentration: HHI, number of companies, size distributions, market shares
Major Players: company profiles and market size ranges
Definition & ClassificationThis U.S. industry comprises establishments primarily engaged in manufacturing in-vivo diagnostic substances and pharmaceutical preparations (except biological) intended for internal and external consumption in dose forms, such as ampoules, tablets, capsules, vials, ointments, powders, solutions, and suspensions. This 6-digit NAICS industry (325412) is under the hierarchy of Pharmaceutical and Medicine Manufacturing Industry (32541), Chemical Manufacturing Subsector (325), and the Manufacturing Sector (31-33). Its SIC equivalent codes are: 2834 - Pharmaceutical Preparations ; and 2835 - In Vitro and In Vivo Diagnostic Substances (except in-vitro diagnostic substances).
Revenue, Profitability & Foreign Trade PreviewThe industry's revenue for the year 2009 was approximately $133.2 billion USD, with an estimated gross profit of 67.29%. Import was valued at $49.3 billion USD from 88 countries. The industry also exported $27.5 billion USD worth of merchandise to 197 countries. Adding import value to and subtracting export value from the industry's shipment value, the total domestic demand for the industry in 2009 was $155.0 billion USD.
Report SummaryThis 172-page research report covers the industry with a comprehensive view and delivers a depth of information in key areas. Supply and demand data covers U.S. shipments and international trade in the context of the industry's capacity utilization. Industry level income statements, balance sheets, and capital expenditure analysis allow for financia
Copyright©2010 PR Newswire.
All rights reserved